FDA approves Heron's Sustol

Heron Therapeutics Inc. (NASDAQ:HRTX) said FDA approved Sustol granisetron extended release ( APF530) in adults in combination with other antiemetics to prevent chemotherapy-induced nausea and vomiting (CINV). Heron expects to launch the therapy next quarter.

On a conference call Wednesday, Heron President and CCO Robert Rosen declined to disclose Sustol's price, but said the company will implement "a performance-based contract that we believe offers sustained value over time." ...